RLMD — Relmada Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $120.70m
- $24.37m
- 25
- 24
- 77
- 37
Annual cashflow statement for Relmada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.3 | -59.5 | -126 | -157 | -98.8 |
| Depreciation | |||||
| Non-Cash Items | 5.31 | 20.8 | 41.7 | 42.6 | 44.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.51 | 10.8 | -7.86 | 10.6 | 3.08 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -10.5 | -27.8 | -91.9 | -104 | -51.7 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -34.4 | -54.1 | 19.7 | 50.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -34.4 | -54.1 | 19.7 | 50.5 |
| Financing Cash Flow Items | — | — | — | 0.374 | -0.098 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17.5 | 28.5 | 188 | 45 | -0.098 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.98 | -33.8 | 41.9 | -39 | -1.3 |